Volumetric Biotechnologies specializes in bioprinting vascularized human tissues using proprietary photoinitiators and polyethylene glycol diacrylate materials. This technology addresses the need for functional tissue constructs in regenerative medicine and drug testing, enhancing the development of complex biological systems.
Funding
$19.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The creation of functional, vascularized human tissues for regenerative medicine and drug testing is limited by the lack of suitable bioprinting materials and technologies. Current methods struggle to produce complex, three-dimensional tissue constructs with the necessary vascular networks for nutrient and waste exchange.
Solution
Volumetric Biotechnologies, now part of 3D Systems, provides specialized bioprinting materials that enable the fabrication of vascularized human tissues. Their core offering includes photoinitiators and polyethylene glycol diacrylate (PEGDA) materials optimized for bioprinting applications. These materials facilitate the creation of complex biological systems, advancing research in regenerative medicine and improving the accuracy of drug testing by providing more physiologically relevant tissue models.
Target Audience
The primary customers are researchers and companies in the fields of regenerative medicine, drug discovery, and tissue engineering who require advanced bioprinting materials for creating functional tissue constructs.
Features
- Lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) Photoinitiator (Sterile-Filtered Aqueous Solution)
- 3400 Da Poly(ethylene glycol) diacrylate (PEGDA) powder
- 6000 Da Poly(ethylene glycol) diacrylate (PEGDA) powder
- GelMA (Sterile-filtered aqueous solution)
- Coming Soon